As we transition into 2026, Medsynapse recognizes that the most significant advancements in healthcare are born from collective expertise. Medical progress is not merely an individual pursuit; it is a testament to the shared intellect, unwavering resilience, and profound professional advocacy that defines our community. Behind every clinical breakt

Introduction: Venous thromboembolism (VTE) remains a significant concern following orthopedic surgeries like total knee arthroplasty (TKA), affecting up to 40-60% of untreated patients despite prophylaxis (1). Current anticoagulants, such as low-molecular-weight heparin (e.g., enoxaparin), effectively reduce VTE but increase bleeding risks, particu

Introduction: Postoperative venous thromboembolism (VTE) remains a common and serious complication following major orthopedic procedures such as total knee arthroplasty (TKA). While conventional anticoagulants reduce VTE risk, their bleeding liability limits use in certain patient populations, especially those at increased hemorrhagic risk (1). Inh

Hello, and a warm welcome to MedX, where we bring you the latest news and insights from the world of medicine. FDA Approves First Gene Therapy for Wiskott-Aldrich Syndrome The FDA has approved the first cell-based gene therapy for Wiskott-Aldrich syndrome, marking a major milestone for patients with this rare and life-threatening genetic condition.

Hello, and a warm welcome to MedX, where we bring you the latest news and insights from the world of medicine.   FDA Approves Targeted Therapy for Relapsed CLL/SLL The U.S. Food and Drug Administration granted traditional approval for a targeted therapy for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphom

Introduction Elranatamab-BCMM is a humanized bispecific antibody that binds B-cell maturation antigen (BCMA) on malignant plasma cells and CD3 on T cells, redirecting cytotoxic activity against multiple myeloma cells (1). In phase 2 MagnetisMM-3, subcutaneous step-up dosing followed by weekly and then biweekly schedules achieved deep responses with

Introduction Venous thromboembolism (VTE)—encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE)—remains a major cause of preventable morbidity and mortality worldwide. Although direct oral anticoagulants (DOACs) and vitamin K antagonists are highly effective for most patients, a small subset continues to experience recurrent thromboti

Introduction Elranatamab-BCMM is a bispecific antibody targeting B-cell maturation antigen (BCMA) on malignant plasma cells and CD3 on T cells, redirecting immune cytotoxicity to eliminate multiple myeloma cells (1). Its subcutaneous administration and step-up dosing schedule are designed to mitigate cytokine release syndrome (CRS) while allowing o

Hello, and a warm welcome to MedX, where we bring you the latest news and insights from the world of medicine.  Novel Bispecific Antibody Shows Major Follicular Lymphoma Benefit The FDA has approved a novel T-cell-engaging bispecific antibody for adults with relapsed or refractory follicular lymphoma, in combination with standard immunotherapy and